NC 181
Alternative Names: NC-181Latest Information Update: 29 Sep 2024
At a glance
- Originator NextCure
- Class Antibodies; Antidementias
- Mechanism of Action Apolipoprotein E4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 01 Aug 2024 NextCure plans to file an IND application with the US FDA in USA for Alzheimer's disease in the mid-2025
- 28 Sep 2023 NC 181 is available for licensing as of 28 Sep 2023. https://www.nextcure.com/partnering-opportunities/
- 26 Sep 2023 Preclinical trials in Alzheimer's disease in USA (Parenteral)